October 18, 2017

Earlier this month, California-based biotech company BridgeBio Pharma announced that it will partner with The University of Texas M.D. Anderson Cancer Center in the development of a new biopharmaceutical firm referred to as Navire Pharma.

In addition to providing $30 million of funds and a team of senior business managers to the project’s development, BridgeBio Pharma will be contributing pharmaceutical and biotechnology executives to the Navire team. These valuable contributions  in conjunction with the UT M.D. Anderson Cancer Center’s intellectual property and its oncolo...

August 22, 2017

As addressed in many of our past articles such as, “Israeli Biotech Company Collaborates with U.S. Agritech Giant” and “Texas and Israel: Both “Lone Star” States in the Fight Against Skin Cancer,” Texas and Israel both economically overlap in the areas of biotechnology and biomedicine and can mutually benefit from more collaboration in these two areas.

One particular example of Israeli success in biotechnology is in the recent $1.1 billion purchase of Israeli drugmaker Neuroderm to Japanese pharma giant Mitsubishi Tanabe last month. As the Times of Israel elaborated in a r...

July 20, 2017

The world-renown Texas Biomedical Research Institute located in San Antonio, Texas, announced on June 19 that it plans to expand its “Biosafety Level 4 Facility” (BSL-4) with the interest of having greater capabilities to find cures to many kinds of infectious diseases.

Texas Biomed Research Institute’s President and CEO Dr. Larry Schlesinger explains this pivotal decision, “The Institute’s current biosafety level 4 laboratory, which is the highest safety level laboratory that allows for the study of the world’s deadliest pathogens, must expand if we are to meet the growin...

June 14, 2017

An Israeli biopharma company may have just created a possible cure for Type-1 Diabetes. Betalin Therapeutics, winner of the annual international MIXiii Biomed 2017 pharma startup competition, has made a micro-pancreas that performs the insulin secreting functions of a healthy non-diabetic pancreas. Type1-diabetes is an autoimmune disease that inhibits the pancreas from carrying out its proper functions in releasing insulin. Rather than transplanting cells that produce insulin to combat this form of diabetes, Betalin Therapeutics has chosen to embark on a more innovative a...

Please reload